These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 26753892)

  • 21. Efficacy and safety of pantoprazole versus ranitidine in the treatment of patients with symptomatic gastroesophageal reflux disease.
    van Zyl J; van Rensburg C; Vieweg W; Fischer R
    Digestion; 2004; 70(1):61-9. PubMed ID: 15297779
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical trial: maintenance intermittent therapy with rabeprazole 20 mg in patients with symptomatic gastro-oesophageal reflux disease - a double-blind, placebo-controlled, randomized study.
    Fass R; Delemos B; Nazareno L; Kao R; Xiang J; Lu Y
    Aliment Pharmacol Ther; 2010 May; 31(9):950-60. PubMed ID: 20132154
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of Amla (Phyllanthus emblica L.) in non-erosive reflux disease: a double-blind, randomized, placebo-controlled clinical trial.
    Karkon Varnosfaderani S; Hashem-Dabaghian F; Amin G; Bozorgi M; Heydarirad G; Nazem E; Nasiri Toosi M; Mosavat SH
    J Integr Med; 2018 Mar; 16(2):126-131. PubMed ID: 29526236
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Challenges of correlating pH change with relief of clinical symptoms in gastro esophageal reflux disease: a phase III, randomized study of Zegerid versus Losec.
    Walker D; Ng Kwet Shing R; Jones D; Gruss HJ; Reguła J
    PLoS One; 2015; 10(2):e0116308. PubMed ID: 25706883
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and Safety of Vonoprazan in Patients With Nonerosive Gastroesophageal Reflux Disease: A Randomized, Placebo-Controlled, Phase 3 Study.
    Kinoshita Y; Sakurai Y; Takabayashi N; Kudou K; Araki T; Miyagi T; Iwakiri K; Ashida K
    Clin Transl Gastroenterol; 2019 Nov; 10(11):e00101. PubMed ID: 31770139
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Symptom-relieving effect of esomeprazole 40 mg daily in patients with heartburn.
    Johnsson F; Hatlebakk JG; Klintenberg AC; Román J
    Scand J Gastroenterol; 2003 Apr; 38(4):347-53. PubMed ID: 12739705
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selective serotonin reuptake inhibitors for the treatment of hypersensitive esophagus: a randomized, double-blind, placebo-controlled study.
    Viazis N; Keyoglou A; Kanellopoulos AK; Karamanolis G; Vlachogiannakos J; Triantafyllou K; Ladas SD; Karamanolis DG
    Am J Gastroenterol; 2012 Nov; 107(11):1662-7. PubMed ID: 21625270
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of esomeprazole on nighttime heartburn and sleep quality in patients with GERD: a randomized, placebo-controlled trial.
    Johnson DA; Orr WC; Crawley JA; Traxler B; McCullough J; Brown KA; Roth T
    Am J Gastroenterol; 2005 Sep; 100(9):1914-22. PubMed ID: 16128933
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Arbaclofen placarbil in GERD: a randomized, double-blind, placebo-controlled study.
    Vakil NB; Huff FJ; Bian A; Jones DS; Stamler D
    Am J Gastroenterol; 2011 Aug; 106(8):1427-38. PubMed ID: 21519360
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cimetidine 800 mg twice daily for healing erosions and ulcers in gastroesophageal reflux disease.
    Palmer RH; Frank WO; Rockhold FW; Wetherington JD; Young MD
    J Clin Gastroenterol; 1990; 12 Suppl 2():S29-34. PubMed ID: 2246493
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lower pH values of weakly acidic refluxes as determinants of heartburn perception in gastroesophageal reflux disease patients with normal esophageal acid exposure.
    de Bortoli N; Martinucci I; Savarino E; Franchi R; Bertani L; Russo S; Ceccarelli L; Costa F; Bellini M; Blandizzi C; Savarino V; Marchi S
    Dis Esophagus; 2016 Jan; 29(1):3-9. PubMed ID: 25212408
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomised clinical trial: arbaclofen placarbil in gastro-oesophageal reflux disease--insights into study design for transient lower sphincter relaxation inhibitors.
    Vakil NB; Huff FJ; Cundy KC
    Aliment Pharmacol Ther; 2013 Jul; 38(2):107-17. PubMed ID: 23721547
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Refractory GERD: increased body mass index is associated with persisting acid exposure but not hypersensitive esophagus or functional heartburn.
    Viazis N; Karamanolis GP; Anastasiou J; Keyoglou A; Vlachogiannakos J; Ladas SD; Karamanolis DG
    Eur J Gastroenterol Hepatol; 2013 Dec; 25(12):1450-5. PubMed ID: 24047861
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Functional heartburn: clinical characteristics and outcome.
    Surdea Blaga T; Dumitrascu D; Galmiche JP; Bruley des Varannes S
    Eur J Gastroenterol Hepatol; 2013 Mar; 25(3):282-90. PubMed ID: 23128061
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical trial: esomeprazole for moderate-to-severe nighttime heartburn and gastro-oesophageal reflux disease-related sleep disturbances.
    Johnson D; Crawley JA; Hwang C; Brown K
    Aliment Pharmacol Ther; 2010 Jul; 32(2):182-90. PubMed ID: 20456306
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Distension during gastroesophageal reflux: effects of acid inhibition and correlation with symptoms.
    Tipnis NA; Rhee PL; Mittal RK
    Am J Physiol Gastrointest Liver Physiol; 2007 Aug; 293(2):G469-74. PubMed ID: 17556589
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cimetidine QID and BID in rapid heartburn relief and healing of lesions in gastroesophageal reflux disease.
    Palmer RH; Miller DM; Hedrich DA; Karlstadt RG
    Clin Ther; 1993; 15(6):994-1001. PubMed ID: 8111819
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Imipramine for Treatment of Esophageal Hypersensitivity and Functional Heartburn.
    Marsden SL; Ford AC
    Am J Gastroenterol; 2016 Sep; 111(9):1358. PubMed ID: 27580782
    [No Abstract]   [Full Text] [Related]  

  • 39. Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease.
    Fass R; Chey WD; Zakko SF; Andhivarothai N; Palmer RN; Perez MC; Atkinson SN
    Aliment Pharmacol Ther; 2009 Jun; 29(12):1261-72. PubMed ID: 19392864
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association between baseline impedance values and response proton pump inhibitors in patients with heartburn.
    de Bortoli N; Martinucci I; Savarino E; Tutuian R; Frazzoni M; Piaggi P; Bertani L; Furnari M; Franchi R; Russo S; Bellini M; Savarino V; Marchi S
    Clin Gastroenterol Hepatol; 2015 Jun; 13(6):1082-8.e1. PubMed ID: 25499991
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.